U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Asciminib (Scemblix): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with 2 or more tyrosine kinase inhibitors [Internet].

Asciminib (Scemblix): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with 2 or more tyrosine kinase inhibitors [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...